{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:07:05Z","timestamp":1774120025202,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.jinf.2011.05.006","type":"journal-article","created":{"date-parts":[[2011,5,22]],"date-time":"2011-05-22T04:46:30Z","timestamp":1306039590000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Reversion rates of QuantiFERON-TB Gold are related to pre-treatment IFN-gamma levels"],"prefix":"10.1016","volume":"63","author":[{"given":"Kosaku","family":"Komiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyuki","family":"Ariga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuyuki","family":"Kurashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syunsuke","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutsuki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"59","key":"10.1016\/j.jinf.2011.05.006_bib1","first-page":"1","article-title":"Centers for disease C, prevention: updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States","volume":"2010","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jinf.2011.05.006_bib2","first-page":"393","article-title":"Guideline for the use of Quantiferon TB-2G","volume":"81","year":"2006","journal-title":"Kekkaku"},{"key":"10.1016\/j.jinf.2011.05.006_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","article-title":"Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update","volume":"149","author":"Pai","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jinf.2011.05.006_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2334-10-57","article-title":"Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country","volume":"10","author":"Dyrhol-Riise","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2011.05.006_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1164\/rccm.200608-1109OC","article-title":"Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens","volume":"175","author":"Chee","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2011.05.006_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1465-9921-8-5","article-title":"Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study","volume":"8","author":"Goletti","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.jinf.2011.05.006_bib7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1164\/rccm.200511-1783OC","article-title":"Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis","volume":"174","author":"Ewer","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2011.05.006_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1183\/09031936.00151309","article-title":"Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens","volume":"36","author":"Chee","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2011.05.006_bib9","first-page":"1146","article-title":"Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis","volume":"12","author":"Katiyar","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jinf.2011.05.006_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s15010-007-6114-z","article-title":"Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment","volume":"35","author":"Pai","year":"2007","journal-title":"Infection"},{"key":"10.1016\/j.jinf.2011.05.006_bib11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial","volume":"360","author":"Benator","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2011.05.006_bib12","first-page":"1059","article-title":"Tuberculosis trials C: the value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse","volume":"12","author":"Hamilton","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jinf.2011.05.006_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2334-6-66","article-title":"Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases","volume":"6","author":"Aiken","year":"2006","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2011.05.006_bib14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.mcp.0000158726.13159.5e","article-title":"Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis","volume":"11","author":"Dheda","year":"2005","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jinf.2011.05.006_bib15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaci.2010.08.011","article-title":"Age-related changes in immune function: effect on airway inflammation","volume":"126","author":"Busse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jinf.2011.05.006_bib16","first-page":"392","article-title":"Survival and relapse rate of tuberculosis patients who successfully completed treatment in Vietnam","volume":"11","author":"Vree","year":"2007","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445311003550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445311003550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:14:49Z","timestamp":1759007689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445311003550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0163445311003550"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2011.05.006","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversion rates of QuantiFERON-TB Gold are related to pre-treatment IFN-gamma levels","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2011.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}